Healthcare >> CEO Interviews >> April 14, 2002

Russell Medford – Atherogenics Inc

RUSSELL M. MEDFORD is scientific co-founder, President and Chief Executive Officer of AtheroGenics, Inc. He has served as a member of AtheroGenics' Board of Directors since the company's inception in 1993. Dr. Medford is also a Director of privately held Inhibitex, Inc. and Somatocor. Dr. Medford serves on the Georgia BioMedical Partnership Board of Directors and is a member of the Metro Atlanta Biotechnology Task Force. Dr. Medford is the recipient of the Ernst & Young Southeast Region 2001 Entrepreneur of the Year award in the emerging category. Since 1989, Dr. Medford has held a number of academic appointments at the Emory University School of Medicine, recently as an Associate Professor of Medicine and Director of Molecular Cardiology, and is currently Clinical Professor (adjunct) of Medicine. Dr. Medford is a molecular cardiologist whose research has focused on the molecular basis of cardiovascular disease. He has published widely in the field of molecular cardiology and holds 11 US patents. Dr. Medford received a BA from Cornell University and an MD with Distinction and a PhD in molecular and cell biology from the Albert Einstein College of Medicine. Dr. Medford completed his residency in internal medicine at the Beth Israel Hospital and his fellowship in cardiology at the Brigham and Women's Hospital and Harvard Medical School, where he also served on the faculty of Medicine. Profile
TWST: Would you give us a brief overview of the history and evolution of

AtheroGenics, Inc.?

Mr. Medford: AtheroGenics was founded in 1993 on a proprietary drug

discovery technology platform